Licensing agreement
Belgium’s UCB Pharma SA has agreed a partnership with the German biotech Wilex AG, under which Wilex will acquire worldwide rights to develop UCB’s entire preclinical oncology portfolio of two small-molecule programmes and three antibody programmes.
UCB retains exclusive rights to take each of the five programmes back in-house following completion of initial clinical feasibility studies, in which case it will assume responsibility for further development and commercialisation.
If UCB decides not to take on a product, Wilex will have rights to develop and commercialise it.
UCB is to invest €10 million in Wilex, and will also make milestone payments of €10 million when the first product enters clinical trials. The deal will give UCB 13 per cent of Wilex’s equity.
Melanie Lee, Executive Vice-President of UCB, said, “This alliance will give UCB the opportunity to focus our R&D priorities in our core indication areas, central nervous system and immunology […] while benefiting from Wilex’s comprehensive oncology expertise, focus and know-how.”
Olaf Wilhelm, Wilex Chairman, said, “We have gained in UCB not only an important development partner, but also a strong strategic investor which will help to further the development of our company.” Wilex was spun out of the Technical University of Munich in 1997.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
